BioCentury | Apr 15, 2013
Company News

Procept, Abbott deal

...by NMR technology (structure activity relationship by nuclear magnetic resonance) to an undisclosed PRCT target. Procept Inc....
BioCentury | Apr 12, 2004
Strategy

Indevus' pipeline

...III 2H04 Aventis PRO 2000 HIV and STD prevention Moving into Ph II/III in 2004 Procept...
BioCentury | Aug 21, 2000
Clinical News

PRO 2000 Gel: Began Phase I/II trial enrollment

...IPIC acquired exclusive global rights to PRO 2000 from Procept Inc. (Cambridge, Mass.), a subsidiary of HeavenlyDoor.com...
BioCentury | Jun 19, 2000
Company News

Interneuron, HeavenlyDoor.com Inc. deal

...milestones and royalties. IPIC will be responsible for further development. PRO 2000 was developed by Procept Inc....
BioCentury | Jun 15, 2000
Company News

Interneuron acquires HIV preventative

...and other sexually transmitted pathogens, from HeavenlyDoor.com (HVDC). PRO 2000, which was developed by HVDC's Procept...
BioCentury | Mar 27, 2000
Clinical News

O6-Benzylguanine (BG): Began Phase II testing

...subsidiary of HeavenlyDoor.com Inc. (HVDC), and the trial is sponsored by the National Cancer Institute. Procept Inc....
...the O6 alkylguanine-DNA alkyltransferase (AGT) DNA repair enzyme Indication: Treat advanced soft tissue sarcoma Status: Procept...
BioCentury | Mar 22, 2000
Clinical News

Procept begins Phase II

...trial of O6-Benzylguanine (BG) chemosensitizing agent with carmustine (BCNU) to treat advanced soft tissue sarcoma. Procept...
BioCentury | Feb 14, 2000
Clinical News

O-6-Benzylguanine (BG): Began Phase II trial

...Phase II trial of Procept’s BG in combination with carmustine to treat cerebral anaplastic gliomas. Procept...
BioCentury | Feb 11, 2000
Clinical News

Procept begins Phase II

Procept ( Cambridge , Mass.), a subsidiary of HeavenlyDoor.com (HVDC), began a U.S. Phase II trial of its 0-6-Benzylguanine chemosensitizing agent in combination with carmustine to treat cerebral anaplastic gliomas. BC Staff...
BioCentury | Feb 7, 2000
Company News

Procept, Heaven's Door Corp. deal

...announced merger with Heaven's Door, a provider of internet funeral services (see BioCentury, Sept. 20). Procept...
...chemosensitizer, to its Pacific Pharmaceuticals Inc. subsidiary (San Diego, Calif.), which will be renamed Procept Inc. Procept...
Items per page:
1 - 10 of 69
BioCentury | Apr 15, 2013
Company News

Procept, Abbott deal

...by NMR technology (structure activity relationship by nuclear magnetic resonance) to an undisclosed PRCT target. Procept Inc....
BioCentury | Apr 12, 2004
Strategy

Indevus' pipeline

...III 2H04 Aventis PRO 2000 HIV and STD prevention Moving into Ph II/III in 2004 Procept...
BioCentury | Aug 21, 2000
Clinical News

PRO 2000 Gel: Began Phase I/II trial enrollment

...IPIC acquired exclusive global rights to PRO 2000 from Procept Inc. (Cambridge, Mass.), a subsidiary of HeavenlyDoor.com...
BioCentury | Jun 19, 2000
Company News

Interneuron, HeavenlyDoor.com Inc. deal

...milestones and royalties. IPIC will be responsible for further development. PRO 2000 was developed by Procept Inc....
BioCentury | Jun 15, 2000
Company News

Interneuron acquires HIV preventative

...and other sexually transmitted pathogens, from HeavenlyDoor.com (HVDC). PRO 2000, which was developed by HVDC's Procept...
BioCentury | Mar 27, 2000
Clinical News

O6-Benzylguanine (BG): Began Phase II testing

...subsidiary of HeavenlyDoor.com Inc. (HVDC), and the trial is sponsored by the National Cancer Institute. Procept Inc....
...the O6 alkylguanine-DNA alkyltransferase (AGT) DNA repair enzyme Indication: Treat advanced soft tissue sarcoma Status: Procept...
BioCentury | Mar 22, 2000
Clinical News

Procept begins Phase II

...trial of O6-Benzylguanine (BG) chemosensitizing agent with carmustine (BCNU) to treat advanced soft tissue sarcoma. Procept...
BioCentury | Feb 14, 2000
Clinical News

O-6-Benzylguanine (BG): Began Phase II trial

...Phase II trial of Procept’s BG in combination with carmustine to treat cerebral anaplastic gliomas. Procept...
BioCentury | Feb 11, 2000
Clinical News

Procept begins Phase II

Procept ( Cambridge , Mass.), a subsidiary of HeavenlyDoor.com (HVDC), began a U.S. Phase II trial of its 0-6-Benzylguanine chemosensitizing agent in combination with carmustine to treat cerebral anaplastic gliomas. BC Staff...
BioCentury | Feb 7, 2000
Company News

Procept, Heaven's Door Corp. deal

...announced merger with Heaven's Door, a provider of internet funeral services (see BioCentury, Sept. 20). Procept...
...chemosensitizer, to its Pacific Pharmaceuticals Inc. subsidiary (San Diego, Calif.), which will be renamed Procept Inc. Procept...
Items per page:
1 - 10 of 69